Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Antisense oligonucleotide: A potential therapeutic intervention for chronic kidney disease

Li, Y., Tan, Y., Zhang, R., Wang, T., Na, N., Zheng, T., Veedu, R.N. and Chen, S. (2022) Antisense oligonucleotide: A potential therapeutic intervention for chronic kidney disease. Kidney and Dialysis, 2 (1). pp. 16-37.

PDF - Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview
PDF (Supplementary Information)
Download (404kB) | Preview
Free to read:
*No subscription required


Chronic kidney disease (CKD) is a global public health issue that places an increasing burden on the healthcare systems of both the developed and developing countries. CKD is a progressive and irreversible condition, affecting approximately 10% of the population worldwide. Patients that have progressed to end-stage renal disease (ESRD) require expensive renal replacement therapy, i.e., dialysis or kidney transplantation. Current CKD therapy largely relies on the use of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs). However, these treatments by no means halt the progression of CKD to ESRD. Therefore, the development of new therapies is urgently needed. Antisense oligonucleotide (ASO) has recently attracted considerable interest as a drug development platform. Thus far, eight ASO-based drugs have been granted approval by the US Food and Drug Administration for the treatment of various diseases. Herein, we review the ASOs developed for the identification of CKD-relevant genes and/or the simultaneous development of the ASOs as potential therapeutics towards treating CKD.

Item Type: Journal Article
Murdoch Affiliation(s): Centre for Molecular Medicine and Innovative Therapeutics
Publisher: MDPI
Copyright: © 2022 by the authors
Item Control Page Item Control Page


Downloads per month over past year